ReviewImmunologic research2008
The evolving role of semaphorins and plexins in the immune system: Plexin-A1 regulation of dendritic cell function.
Review in Immunologic research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- The FLRT3-UNC5B checkpoint pathway inhibits T cell-based cancer immunotherapies.Science advances · 2024Article
- Semaphorin 6 Family-An Important Yet Overlooked Group of Signaling Proteins Involved in Cancerogenesis.Cancers · 2023Review
- SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma.Journal of experimental & clinical cancer research : CR · 2022Article
- PlexinA1 activation induced by β2-AR promotes epithelial-mesenchymal transition through JAK-STAT3 signaling in human gastric cancer cells.Journal of Cancer · 2022Article
- Chronic Stress Activates PlexinA1/VEGFR2-JAK2-STAT3 in Vascular Endothelial Cells to Promote Angiogenesis.Frontiers in oncology · 2021Article
- Disruption of Sema3A/Plexin-A1 inhibitory signalling in oligodendrocytes as a therapeutic strategy to promote remyelination.EMBO molecular medicine · 2019Article
- Gene Expression Profiling in Peripheral Blood Cells and Synovial Membranes of Patients with Psoriatic Arthritis.PloS one · 2015Article
- Semaphorins: their dual role in regulating immune-mediated diseases.Clinical reviews in allergy & immunology · 2014Review
- Plexin structures are coming: opportunities for multilevel investigations of semaphorin guidance receptors, their cell signaling mechanisms, and functions.Cellular and molecular life sciences : CMLS · 2012Review
- Structural basis of Rnd1 binding to plexin Rho GTPase binding domains (RBDs).The Journal of biological chemistry · 2011Article
- Article
- High-throughput discovery and characterization of fetal protein trafficking in the blood of pregnant women.Proteomics. Clinical applications · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Semaphorin and plexin proteins were originally identified for their important axon guidance regulation. In recent years, their role within the immune system has been discovered. Semaphorins are considered the ligands to the plexin receptors, and together, they mediate cell-cell communication. Initially, through gene knock-out and knock-down studies, simple ligand-receptor pairings that regulate specific cellular interactions were discovered, such as between T cells and dendritic cells. However, more recent data indicate that individual cell types express multiple semaphorin and plexin proteins, engendering complex interactions involving multiple ligand-receptor pairs and multiple cell types. In this review, we describe contributions from our lab elucidating Plexin-A1 regulation of the immune system and our more recent findings of Semaphorin 6D regulation of T-cell immunity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.